Difficulty: Medium
Average Score: 95%
Practice
Inclisiran used in the treatment of dyslipidemia is chemically a
Correct answer
A
Rationale
In this question, the correct answer is A) Synthetic RNA. Inclisiran is a novel therapeutic option for dyslipidemia that works by inhibiting production of the protein PCSK9, ultimately leading to decreased LDL cholesterol levels.
A) Synthetic RNA is the correct answer because Inclisiran is a small interfering RNA (siRNA) molecule designed to target and inhibit the production of specific messenger RNA molecules involved in cholesterol metabolism.
B) Synthetic histone, C) Synthetic DNA, and D) Synthetic mitochondria are incorrect because they are not directly related to the mechanism of action of Inclisiran in dyslipidemia treatment. Histones are proteins that DNA wraps around, DNA is the genetic material, and mitochondria are organelles responsible for energy production in cells.
Understanding the chemical composition of medications used in pediatric cardiovascular disorders is crucial for nurses to ensure safe and effective administration. Knowledge of pharmacology allows healthcare professionals to make informed decisions, monitor for potential adverse effects, and provide patient education regarding medication management. In this case, knowing that Inclisiran is a synthetic RNA molecule helps nurses comprehend its mechanism of action and its role in managing dyslipidemia in pediatric patients.
A) Synthetic RNA is the correct answer because Inclisiran is a small interfering RNA (siRNA) molecule designed to target and inhibit the production of specific messenger RNA molecules involved in cholesterol metabolism.
B) Synthetic histone, C) Synthetic DNA, and D) Synthetic mitochondria are incorrect because they are not directly related to the mechanism of action of Inclisiran in dyslipidemia treatment. Histones are proteins that DNA wraps around, DNA is the genetic material, and mitochondria are organelles responsible for energy production in cells.
Understanding the chemical composition of medications used in pediatric cardiovascular disorders is crucial for nurses to ensure safe and effective administration. Knowledge of pharmacology allows healthcare professionals to make informed decisions, monitor for potential adverse effects, and provide patient education regarding medication management. In this case, knowing that Inclisiran is a synthetic RNA molecule helps nurses comprehend its mechanism of action and its role in managing dyslipidemia in pediatric patients.